CRISPR Therapeutics AG CRSP 深 沪
等待开盘 10-16 09:30:00 美东时间
71.82
+2.440
+3.52%
华盛通- 最 高73.09
- 今 开70.01
- 成交量 236.16万股
- 最 低 69.80
- 昨 收 69.38
- 总市值 65.32亿
- 52周最高 78.48
- 市盈率 静 --
- 换手率 2.60%
- 52周最低 30.04
- 委 比 -13.56%
- 总股本 9095.04万
- 历史最高 220.20
- 量 比 0.65
- 振 幅 4.74%
- 历史最低 13.50
- 每 手 1
- 风险率 9.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
深度｜诺奖背后生物技术公司力量迅速崛起，科学家创业有何秘诀？
在做科研的时候，一定是挑专业领域里最难的问题去攻克，而在创办企业的时候，应该要挑最容易的那部分去做，这样才最有可能将科研成果转化为实际的经济收益。 诺贝...
10-12 14:06
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $81 Price Target
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $81 price target.
10-10 23:04
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
CRISPR Therapeutics reported promising preclinical data for CTX460, their lead candidate using the SyNTase gene editing platform, targeting Alpha-1 Antitrypsin Deficiency (AATD). Data showed >90% mRNA correction, a 5-fold increase in AAT levels, and over 99% M-AAT:Z-AAT ratio in animal models, with durable effects up to 9 weeks. CTX460 is expected to enter clinical trials in mid-2026, representing a potential best-in-class treatment for AATD.
10-10 12:00
Shares of precious metals stocks are trading lower amid a pullback after a recent rally.
Shares of precious metals stocks are trading lower amid a pullback after a rece...
10-09 23:41
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
CRISPR Therapeutics announced the acceptance of an abstract for oral presentation at the ESGCT 2025 Annual Congress, detailing their novel SyNTase gene editing technology. This technology enables single-dose in vivo gene correction for treating Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder. SyNTase combines compact Cas9 proteins with engineered polymerases, offering greater efficiency and precision in gene editing compared to exi...
10-01 12:00
小核酸公司靖因药业港交所递表：上半年扭亏，暂无商业化产品收入
又有小核酸疗法公司计划港股上市。 9月28日，靖因药业向港交所递交上市申请，高盛、海通国际、汇丰为联席保荐人。靖因药业由OrbiMed Entities及 C...
09-29 18:35
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Morningstar to Acquire CRSP for $375 Million
The latest update is out from Morningstar ( ($MORN) ). On September 23, 2025, M...
09-23 20:17
